Phio Pharmaceuticals Corp. has recently secured a patent from the United States Patent and Trademark Office for their innovative INTASYL Compounds, RXI-185 and RXI-231, designed to combat age-related skin issues such as photo-aging and dermal hyperpigmentation.
RXI-185 targets the suppression of MMP1 protein, preventing UV-induced collagen breakdown and enhancing skin thickness, elasticity, and wrinkles. Meanwhile, RXI-231 works to reduce tyrosinase levels, resulting in decreased melanin and pigmentation in the skin.
This patent approval bolsters Phio’s position in the skincare industry, adding to their extensive portfolio of 81 patents, with a focus on their INTASYL siRNA gene silencing technology.
PHIO Stock Shows Promising Growth with Significant Price Increase – March 6, 2024
On March 6, 2024, PHIO stock showed some promising signs of growth as it experienced a significant increase in its price momentum. The stock opened at $0.91, which was $0.05 higher than its previous close. Throughout the trading day, PHIO shares continued to rise, closing at $1.03 with a $0.12 increase from the previous close, marking a 13.95% rise.
Investors and analysts will be watching closely to see if PHIO can sustain this positive momentum in the days and weeks ahead. If the stock is able to break through its 200-day moving average and continue to climb, it could signal a potential turnaround for PHIO. However, if the stock struggles to maintain its gains and falls back below its current levels, it could indicate that the downward trend may continue.
As always, it is important for investors to conduct their own research and analysis before making any investment decisions. Stock prices can be volatile and unpredictable, so it is crucial to stay informed and be prepared for any potential outcomes.
PHIO Stock Performance Analysis: Net Income and EPS Trends Revealed
On March 6, 2024, PHIO stock showed some interesting performances based on the financial data available. Despite the lack of information on total revenue, the net income figures provide some insights into the company’s financial health.
According to CNN Money, PHIO reported a net income of -$11.48 million over the past year, which represents a 13.6% increase compared to the previous year. However, in the third quarter of the same year, the net income decreased to -$2.78 million, a 9.06% decrease from the previous quarter. This fluctuation in net income could indicate some volatility in the company’s financial performance.
Furthermore, the earnings per share (EPS) also saw some changes over the same period. The EPS was reported at -$10.10 for the past year, showing an 18.72% increase compared to the previous year. In the third quarter, the EPS improved to -$1.14, marking a 22.74% increase from the previous quarter. This increase in EPS could be a positive sign for investors, indicating potential growth in the company’s profitability.
Overall, while the lack of total revenue data makes it challenging to assess the full financial picture of PHIO, the net income and EPS figures suggest some positive trends in the company’s financial performance. Investors may want to keep an eye on future financial reports and market developments to make informed decisions about investing in PHIO stock.
